The Role of Leukotrienes Inhibitors in the Management of Chronic Inflammatory Diseases.

IF 4.2 Q3 Pharmacology, Toxicology and Pharmaceutics
Deepak Meshram, Khushbo Bhardwaj, Charulata Rathod, Gail B Mahady, Kapil K Soni
{"title":"The Role of Leukotrienes Inhibitors in the Management of Chronic Inflammatory Diseases.","authors":"Deepak Meshram,&nbsp;Khushbo Bhardwaj,&nbsp;Charulata Rathod,&nbsp;Gail B Mahady,&nbsp;Kapil K Soni","doi":"10.2174/1872213X14666200130095040","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Leukotrienes are powerful mediators of inflammation and interact with specific receptors in target cell membrane to initiate an inflammatory response. Thus, Leukotrienes (LTs) are considered to be potent mediators of inflammatory diseases including allergic rhinitis, inflammatory bowel disease and asthma. Leukotriene B4 and the series of cysteinyl leukotrienes (C4, D4, and E4) are metabolites of arachidonic acid metabolism that cause inflammation. The cysteinyl LTs are known to increase vascular permeability, bronco-constriction and mucus secretion.</p><p><strong>Objectives: </strong>To review the published data for leukotriene inhibitors of plant origin and the recent patents for leukotriene inhibitors, as well as their role in the management of inflammatory diseases.</p><p><strong>Methods: </strong>Published data for leukotrienes antagonists of plant origin were searched from 1938 to 2019, without language restrictions using relevant keywords in both free text and Medical Subject Headings (MeSH terms) format. Literature and patent searches in the field of leukotriene inhibitors were carried out by using numerous scientific databases including Science Direct, PubMed, MEDLINE, Google Patents, US Patents, US Patent Applications, Abstract of Japan, German Patents, European Patents, WIPO and NAPRALERT. Finally, data from these information resources were analyzed and reported in the present study.</p><p><strong>Results: </strong>Currently, numerous anti-histaminic medicines are available including chloropheneremine, brompheniramine, cetirizine, and clementine. Furthermore, specific leukotriene antagonists from allopathic medicines are also available including zileuton, montelukast, pranlukast and zafirlukast and are considered effective and safe medicines as compared to the first generation medicines. The present study reports leukotrienes antagonistic agents of natural products and certain recent patents that could be an alternative medicine in the management of inflammation in respiratory diseases.</p><p><strong>Conclusion: </strong>The present study highlights recent updates on the pharmacology and patents on leukotriene antagonists in the management of inflammation respiratory diseases.</p>","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":"14 1","pages":"15-31"},"PeriodicalIF":4.2000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on inflammation & allergy drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1872213X14666200130095040","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 7

Abstract

Background: Leukotrienes are powerful mediators of inflammation and interact with specific receptors in target cell membrane to initiate an inflammatory response. Thus, Leukotrienes (LTs) are considered to be potent mediators of inflammatory diseases including allergic rhinitis, inflammatory bowel disease and asthma. Leukotriene B4 and the series of cysteinyl leukotrienes (C4, D4, and E4) are metabolites of arachidonic acid metabolism that cause inflammation. The cysteinyl LTs are known to increase vascular permeability, bronco-constriction and mucus secretion.

Objectives: To review the published data for leukotriene inhibitors of plant origin and the recent patents for leukotriene inhibitors, as well as their role in the management of inflammatory diseases.

Methods: Published data for leukotrienes antagonists of plant origin were searched from 1938 to 2019, without language restrictions using relevant keywords in both free text and Medical Subject Headings (MeSH terms) format. Literature and patent searches in the field of leukotriene inhibitors were carried out by using numerous scientific databases including Science Direct, PubMed, MEDLINE, Google Patents, US Patents, US Patent Applications, Abstract of Japan, German Patents, European Patents, WIPO and NAPRALERT. Finally, data from these information resources were analyzed and reported in the present study.

Results: Currently, numerous anti-histaminic medicines are available including chloropheneremine, brompheniramine, cetirizine, and clementine. Furthermore, specific leukotriene antagonists from allopathic medicines are also available including zileuton, montelukast, pranlukast and zafirlukast and are considered effective and safe medicines as compared to the first generation medicines. The present study reports leukotrienes antagonistic agents of natural products and certain recent patents that could be an alternative medicine in the management of inflammation in respiratory diseases.

Conclusion: The present study highlights recent updates on the pharmacology and patents on leukotriene antagonists in the management of inflammation respiratory diseases.

白三烯抑制剂在慢性炎性疾病治疗中的作用
背景:白三烯是一种强大的炎症介质,可与靶细胞膜上的特定受体相互作用,从而引发炎症反应。因此,白三烯(lt)被认为是炎症性疾病的有效介质,包括过敏性鼻炎、炎症性肠病和哮喘。白三烯B4和一系列半胱氨酸白三烯(C4、D4和E4)是花生四烯酸代谢的代谢物,引起炎症。已知半胱氨酸LTs可增加血管通透性、支气管收缩和粘液分泌。目的:回顾植物来源的白三烯抑制剂的已发表数据和最近的白三烯抑制剂专利,以及它们在炎症性疾病管理中的作用。方法:检索1938年至2019年已发表的植物来源白三烯拮抗剂的数据,不受语言限制,使用自由文本和医学主题词(MeSH terms)格式的相关关键词。通过Science Direct、PubMed、MEDLINE、Google Patents、US Patents、US patent Applications、Abstract of Japan、German Patents、European Patents、WIPO和NAPRALERT等科学数据库对白三烯抑制剂领域的文献和专利进行检索。最后,本研究对这些信息资源的数据进行分析和报告。结果:目前,抗组胺药物有很多,包括氯苯那明、溴苯那明、西替利嗪和克莱门汀。此外,来自对抗性药物的特异性白三烯拮抗剂也可用,包括zileuton、孟鲁司特、pranlukast和zafirlukast,与第一代药物相比,它们被认为是有效和安全的药物。本研究报告了白三烯拮抗剂的天然产物和某些最近的专利,可能是在呼吸道疾病的炎症管理的替代药物。结论:本研究重点介绍了白三烯拮抗剂在炎症性呼吸道疾病治疗中的药理学和专利的最新进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.90
自引率
0.00%
发文量
0
期刊介绍: Recent Patents on Inflammation & Allergy Drug Discovery publishes review articles by experts on recent patents in the field of inflammation and allergy drug discovery e.g. on novel bioactive compounds, analogs and targets. A selection of important and recent patents in the field is also included in the journal. The journal is essential reading for all researchers involved in inflammation and allergy drug design and discovery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信